文摘
Proteases that are expressed during the erythocytic stage of Plasmodium falciparum are newly exploreddrug targets for the treatment of malaria. We report here the discovery of potent inhibitors of PfA-M1, ametallo-aminopeptidase of the parasite. These compounds are based on a malonic hydroxamic template andpresent a very good selectivity toward neutral aminopeptidase (APN-CD13), a related protease in mammals.Structure-activity relationships in these series are described. Further optimization of the best inhibitor yieldeda nanomolar, selective inhibitor of PfA-M1. This inhibitor displays good physicochemical and pharmacokineticproperties and a promising antimalarial activity.